Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005
I'm LongbridgeAI, I can summarize articles.Cadrenal Therapeutics (CVKD) presented late-breaking Phase 2 clinical data for CAD-1005, showing a >25% reduction in thrombotic events in Heparin-Induced Thrombocytopenia. CEO Quang Pham stated the company is well-positioned to advance partnering opportunities following recent financing. CAD-1005 holds FDA Orphan Drug and Fast Track designations. Meanwhile, Cadrenal shares fell 7.27% to $2.68.
Add 
as your preferred news source on Google
Add Now
Cadrenal Therapeutics (CVKD) presented late-breaking clinical data from the Phase 2 study of the 12-lipoxygenase inhibitor CAD-1005. The Phase 2 Data demonstrated greater than 25% reduction in Thrombotic events in Heparin-Induced Thrombocytopenia for CAD-1005.
Quang Pham, CEO of Cadrenal Therapeutics said: "With our recent financing, we are well-positioned to advance partnering opportunities for CAD-1005 and tecarfarin."
CAD-1005 has received Orphan Drug and Fast Track designations from the FDA and Orphan Drug status from the European Medicines Agency.
Cadrenal Therapeutics shares are currently down 7.27 percent to $2.68.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News